1
|
Blay JY, Casali P, Bouvier C, Dehais C, Galloway I, Gietema J, Halámková J, Hindi N, Idbaih A, Kinloch E, Klümpen HJ, Kolarova T, Kopeckova K, Lovey J, Magalhaes M, Oselin K, Piperno-Neumann S, Ravnsbaek A, Rogasik M, Safwat A, Scheipl S, Seckl M, Taylor J, Temnyk M, Trama A, Urbonas M, Wartenberg M, Weinman A. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open 2021; 6:100174. [PMID: 34139485 PMCID: PMC8219752 DOI: 10.1016/j.esmoop.2021.100174] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/12/2021] [Accepted: 05/13/2021] [Indexed: 11/04/2022] Open
Affiliation(s)
- J-Y Blay
- Department of Medical Oncology, Centre Leon Berard & Centre de Recherche en Cancérologie de Lyon (CRCL) & Université Claude Bernard Lyon 1, Lyon, France.
| | - P Casali
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - C Bouvier
- Neuroendocrine Cancer Unit, Royal Free Hospital, London, UK
| | - C Dehais
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | - I Galloway
- Melanoma Patient Network Europe, OcuMel, Birmingham, UK
| | - J Gietema
- Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands
| | - J Halámková
- Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - N Hindi
- Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Virgen, Virgen del Rocío University Hospital, Seville, Spain
| | - A Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | | | - H-J Klümpen
- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - T Kolarova
- International Neuroendocrine Cancer Alliance, Boston, USA
| | - K Kopeckova
- Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
| | - J Lovey
- National Institute of Oncology, Budapest, Hungary
| | - M Magalhaes
- Oncology Department, Centro Hospitalar e Universitário Universitário do Porto, Porto, Portugal
| | - K Oselin
- Department of Chemotherapy, Clinic of Haematology and Oncology, North Estonia Medical Centre Foundation, Tallinn, Estonia
| | | | - A Ravnsbaek
- Oncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark
| | - M Rogasik
- Research and Innovation Department, Centre Léon Bérard, Lyon, France
| | - A Safwat
- Oncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark
| | - S Scheipl
- Medical University of Graz, Graz, Austria
| | - M Seckl
- Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK
| | - J Taylor
- Thyroid Cancer Alliance, Rotterdam, The Netherlands
| | - M Temnyk
- Maria Skłodowska Curie Institute, Warsaw, Poland
| | - A Trama
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - M Urbonas
- Lithuanian University of Health Sciences, Department of Neurosurgery, Kaunas, Lithuania
| | | | - A Weinman
- EURORDIS-Rare Diseases Europe (European Patient Organisation for Rare Diseases)
| |
Collapse
|
3
|
Saghatchian M, Hummel H, Otter R, de Valeriola D, van Harten W, Paradiso A, Lovey J, Kasler M, Fumoleau P, Ringborg U, Tursz T. Validation of a global self-assessment and peer-review quality programme dedicated to comprehensive cancer centres: A method to assess, improve and promote quality of integrated care, research, and education in cancer centers. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e17565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17565 Background: Oncology is a specialty requiring a combination of multidisciplinary expertises, novel technology, integration of innovation into care and research efforts in order to improve the quality of life and survival of patients. Provision of high-quality care and improvement of disease outcome should be promoted in cancer centers. Methods: The Organization of European Cancer Institutes developed an Accreditation Programme combining: 1-a quantitative questionnaire assessing the human, technical and financial resources and activities in care, research and education dedicated to oncology; 2- a set of standards and criteria for high-quality cancer management integrated in an electronic tool with a scoring system of compliance; 3- a peer-review process for review of the self-assessment outcome and on-site visits; 4- a report and improvement plan allowing to designate comprehensive cancer centers complying with required criteria for high-quality comprehensive cancer patient management. All components of the Accreditation Programme were tested in 8 different voluntary cancer centers in Europe. The objectives were to assess the feasibility, reproducibility and acceptance of the Accreditation Programme; to improve the standards and criteria in terms of understanding and consensus; to validate the peer review methodology and establish a method for reporting and implementing an improvement plan; to provide with a preliminary system of designation of comprehensive cancer centers based on criteria of high-quality integrated research, care and education. Results: The 2 consecutive pilot tests allowed to validate 1- relevant items for the quantitative questionnaire; 2-criteria and standards for high-quality integrated multidisciplinary cancer patient's management. 3-The impact of the Accreditation Programme on improvement of patients management and professionals involvement. Conclusions: The OECI Accreditation Programme is ready for dissemination. Participation to the Programme allows development of improvement plans for innovative and integrated comprehensive cancer patients management in cancer centers. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Saghatchian
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - H. Hummel
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - R. Otter
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - D. de Valeriola
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - W. van Harten
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - A. Paradiso
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - J. Lovey
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - M. Kasler
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - P. Fumoleau
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - U. Ringborg
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| | - T. Tursz
- Institut Gustave Roussy, Paris, France; Integraal Kankercentrum Noord-Nederland, Groningen, Netherlands; Institut Jules Bordet, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, Netherlands; Istituto Tumori Giovani Paolo II, Bari, Italy; National Institute of Oncology, Budapest, Hungary; Centre George-François Leclerc, Dijon, France; Cancer Center Karolinska, Stockholm, Sweden
| |
Collapse
|